Perspective Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CATX NYSE American 2830 www.perspectivetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Perspective Therapeutics, Inc.

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Jul 29th, 2026 7:55 am
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs - Jul 28th, 2026 4:30 am
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 - Jul 17th, 2026 10:22 am
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Jul 16th, 2026 7:40 am
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - Jul 8th, 2026 4:30 am
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Jul 5th, 2026 4:08 pm
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Jun 3rd, 2026 12:06 pm
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - Jun 3rd, 2026 4:30 am
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma - May 21st, 2026 3:51 pm
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies - May 18th, 2026 4:30 am
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results - May 11th, 2026 2:07 pm
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 5:05 pm
Perspective Therapeutics to Provide Several Upcoming Corporate Updates - Apr 24th, 2026 4:30 am
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting - Apr 20th, 2026 4:00 am
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Apr 2nd, 2026 5:00 am
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - Mar 17th, 2026 2:45 pm
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results - Mar 16th, 2026 2:07 pm
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Feb 17th, 2026 6:42 pm
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results - Feb 17th, 2026 5:00 am
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed? - Feb 3rd, 2026 11:12 pm